Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Rommel

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Current Topics in Microbiology and Immunology|July 2, 2010
Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseasesChristian Rommel
Current Pharmaceutical Design|June 8, 2004
Phosphoinositide 3-kinases as targets for therapeutic interventionReinhard Wetzker, Christian Rommel
Nature Biotechnology|July 13, 2011
Next-generation flow cytometryMatthew R Janes, Christian Rommel
Cancer Discovery|May 16, 2012
PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinicDavid A Fruman, Christian Rommel
Nature Reviews. Drug Discovery|February 1, 2014
PI3K and cancer: lessons, challenges and opportunitiesDavid A Fruman, Christian Rommel
Nature Reviews. Immunology|February 10, 2007
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?Christian Rommel, Montserrat Camps, Hong Ji
Journal of Molecular Medicine (Berlin, Germany)|August 23, 2006
Decompartmentalizing target validation-thinking outside the pipeline boxesRob Hooft van Huijsduijnen, Christian Rommel
Nature Reviews. Drug Discovery|November 3, 2006
PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?Thomas Rückle, Matthias K Schwarz, Christian Rommel
Current Topics in Microbiology and Immunology|June 16, 2010
PI3K: from the bench to the clinic and backBart Vanhaesebroeck, Peter K Vogt, Christian Rommel
Nature Reviews. Drug Discovery|May 3, 2007
Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responsesKate L Jeffrey, Montserrat Camps, Christian Rommel, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Current Topics in Microbiology and Immunology|July 2, 2010
Taking PI3Kδ and PI3Kγ one step ahead: dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseasesChristian Rommel
Current Pharmaceutical Design|June 8, 2004
Phosphoinositide 3-kinases as targets for therapeutic interventionReinhard Wetzker, Christian Rommel
Nature Biotechnology|July 13, 2011
Next-generation flow cytometryMatthew R Janes, Christian Rommel
Cancer Discovery|May 16, 2012
PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinicDavid A Fruman, Christian Rommel
Nature Reviews. Drug Discovery|February 1, 2014
PI3K and cancer: lessons, challenges and opportunitiesDavid A Fruman, Christian Rommel
Nature Reviews. Immunology|February 10, 2007
PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?Christian Rommel, Montserrat Camps, Hong Ji
Journal of Molecular Medicine (Berlin, Germany)|August 23, 2006
Decompartmentalizing target validation-thinking outside the pipeline boxesRob Hooft van Huijsduijnen, Christian Rommel
Nature Reviews. Drug Discovery|November 3, 2006
PI3Kgamma inhibition: towards an 'aspirin of the 21st century'?Thomas Rückle, Matthias K Schwarz, Christian Rommel
Current Topics in Microbiology and Immunology|June 16, 2010
PI3K: from the bench to the clinic and backBart Vanhaesebroeck, Peter K Vogt, Christian Rommel
Nature Reviews. Drug Discovery|May 3, 2007
Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responsesKate L Jeffrey, Montserrat Camps, Christian Rommel, et al.
Pageof 6